Bhandari Renu, Ogeyingbo Opemipo D, Kareem Roaa, Gyawali Mallika, Venkatesan Nanditha, Ahmed Rowan, Botleroo Rinky A, Elshaikh Abeer O
Internal Medicine/Family Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
Internal Medicine, Manipal College of Medical Sciences, Kaski, NPL.
Cureus. 2021 Sep 5;13(9):e17729. doi: 10.7759/cureus.17729. eCollection 2021 Sep.
Ulcerative colitis (UC) is an inflammatory bowel disease and causes inflammation and ulcer of the colon. Vedolizumab is a newer biological agent with an inhibitory effect on α4β7 integrin approved for moderate to severe UC patients. Our study reviewed the clinical response, clinical remission, and mucosal healing of vedolizumab in moderate to severe UC management. Using Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we conducted a literature search in PubMed, Google Scholar, and Science Direct, and nine studies were included in the systematic review. At week six, vedolizumab showed a significant clinical response. At week 52, vedolizumab showed significant mucosal healing and clinical remission. The most commonly associated adverse effects are nasopharyngitis, oropharyngeal infection, and gastrointestinal infection. However, additional clinical trials and observational studies with longer follow-ups are required to study the efficacy and safety of the drug.
溃疡性结肠炎（UC）是一种炎症性肠病，可导致结肠炎症和溃疡。维多珠单抗是一种新型生物制剂，对α4β7整合素具有抑制作用，已被批准用于中重度UC患者。我们的研究回顾了维多珠单抗在中重度UC治疗中的临床反应、临床缓解和黏膜愈合情况。我们按照系统评价和Meta分析的首选报告项目（PRISMA）指南，在PubMed、谷歌学术和科学Direct数据库中进行了文献检索，9项研究被纳入该系统评价。在第6周时，维多珠单抗显示出显著的临床反应。在第52周时，维多珠单抗显示出显著的黏膜愈合和临床缓解。最常见的相关不良反应是鼻咽炎、口咽感染和胃肠道感染。然而，需要进行更多随访时间更长的临床试验和观察性研究，以研究该药物的疗效和安全性。
